ClinicalTrialsFinder
RecruitingNCT03308474

Myeloma Registry Platform (MYRIAM)

Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)

Sponsor

iOMEDICO AG

Enrollment

2,200 participants

Start Date

Sep 25, 2017

Study Type

OBSERVATIONAL

Conditions

Multiple Myeloma

Summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This registry study is collecting real-world data on patients with multiple myeloma (a type of blood cancer) who are receiving treatment, including information on quality of life, treatment outcomes, and patient-reported experiences. **You may be eligible if...** - You have been diagnosed with multiple myeloma that requires drug treatment - You are 18 years old or older - You are willing to give written consent - (For the quality-of-life sub-study) You are willing to complete questionnaires about your health **You may NOT be eligible if...** - You are not receiving systemic (drug-based) treatment for myeloma - You are under 18 years old - You are unwilling to give consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERRoutine care as per site standard.

Physician's choice according to patient's needs.

Locations(1)

Multiple sites all over germany

Multiple Sites, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03308474

Related Trials

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT0605740233 locations

64Cu-LLP2A for Imaging Hematologic Malignancies

NCT066361751 location

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

NCT074543827 locations

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575273 locations